Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D3OWG9
|
|||
| Drug Name |
M1774
|
|||
| Synonyms |
674783-97-2; 9-Mesityl-10-methylacridinium Perchlorate; 10-methyl-9-(2,4,6-trimethylphenyl)acridin-10-ium;perchlorate; MFCD09038536; Acridinium, 10-methyl-9-(2,4,6-trimethylphenyl)-, perchlorate; ACMC-209nz7; 9-Mesityl-10-methyl-10-acridinium Perchlorate; [Acr-Mes]+(ClO4)-; SCHEMBL10009695; 10-Methyl-9-(2,4,6-trimethylphenyl)acridinium Perchlorate; DTXSID60580419; ANW-35345; AKOS015843774; SY076797; 9-mesityl-10-methyl-acridinium perchlorate; CS-0103389; 9-Mesityl-10-methylacridin-10-ium perchlorate; 9-Mesityl-10-methylacridinium perchlorate, 95%; 9-Mesityl-10-methylacridinium perchlorate, AldrichCPR; 10-METHYL-9-(2,4,6-TRIMETHYLPHENYL)ACRIDIN-10-IUM PERCHLORATE
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Solid tumour/cancer [ICD-11: 2A00-2F9Z; ICD-10: C00-D48; ICD-9: 140-199] | Phase 1 | [1] | |
| Company |
EMD Serono
|
|||
| Structure |
 |
Download2D MOL
|
||
| Formula |
C23H22ClNO4
|
|||
| Canonical SMILES |
CC1=CC(=C(C(=C1)C)C2=C3C=CC=CC3=[N+](C4=CC=CC=C42)C)C.[O-]Cl(=O)(=O)=O
|
|||
| InChI |
1S/C23H22N.ClHO4/c1-15-13-16(2)22(17(3)14-15)23-18-9-5-7-11-20(18)24(4)21-12-8-6-10-19(21)23;2-1(3,4)5/h5-14H,1-4H3;(H,2,3,4,5)/q+1;/p-1
|
|||
| InChIKey |
LFMBERYWDLWXNO-UHFFFAOYSA-M
|
|||
| CAS Number |
CAS 674783-97-2
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Serine/threonine-protein kinase ATR (FRP1) | Target Info | Inhibitor | [2] |
| KEGG Pathway | Fanconi anemia pathway | |||
| Cell cycle | ||||
| p53 signaling pathway | ||||
| HTLV-I infection | ||||
| Panther Pathway | p53 pathway | |||
| p53 pathway feedback loops 2 | ||||
| Pathway Interaction Database | Fanconi anemia pathway | |||
| ATR signaling pathway | ||||
| Signaling events mediated by TCPTP | ||||
| Circadian rhythm pathway | ||||
| BARD1 signaling events | ||||
| p53 pathway | ||||
| Reactome | Meiotic synapsis | |||
| Activation of ATR in response to replication stress | ||||
| Regulation of HSF1-mediated heat shock response | ||||
| HDR through Single Strand Annealing (SSA) | ||||
| Processing of DNA double-strand break ends | ||||
| Presynaptic phase of homologous DNA pairing and strand exchange | ||||
| G2/M DNA damage checkpoint | ||||
| WikiPathways | DNA Damage Response | |||
| Meiotic Synapsis | ||||
| Prostate Cancer | ||||
| Integrated Breast Cancer Pathway | ||||
| Integrated Cancer pathway | ||||
| Cell Cycle | ||||
| Cell Cycle Checkpoints | ||||
| miRNA Regulation of DNA Damage Response | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT04170153) M1774 in Participants With Metastatic or Locally Advanced Unresectable Solid Tumors. U.S. National Institutes of Health. | |||
| REF 2 | National Cancer Institute Drug Dictionary (drug name M1774). | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.